Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOVUE-300 vs HEXABRIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Iodinated radiocontrast agent that attenuates X-rays, providing enhanced visualization of vascular structures and body cavities during imaging procedures.
Hexabrix is an ionic, high-osmolar iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures. Its mechanism is physical rather than pharmacological, based on iodine's atomic number and density.
Intravascular administration for radiography (e.g., angiography, urography),Intrathecal administration for myelography,Intracavitary administration for arthrography, hysterosalpingography, etc.
Intravascular administration for arteriography, venography, and computed tomography (CT) imaging,Intrathecal administration for myelography (lumbar, thoracic, cervical, and total columnar myelography),Off-label: Arthrography, hysterosalpingography, and ductography
Intravenous: 50-150 m L (up to 300 mg iodine/kg) as a bolus or infusion; intra-arterial: 5-40 m L depending on procedure; intrathecal: 8-15 m L. Maximum total iodine dose: 300 mg iodine/kg.
Intravenous: 0.3-0.6 m L/kg (maximum 100 m L) for urography; 40-80 m L for CT enhancement.
Terminal elimination half-life in patients with normal renal function is approximately 2 hours. In patients with moderate to severe renal impairment (creatinine clearance <30 m L/min), the half-life can be prolonged up to 20–40 hours, requiring dose adjustment.
Terminal elimination half-life: 1.5–2 hours in adults (prolonged in renal impairment; up to 30 hours in severe CKD)
Not metabolized; excreted unchanged by glomerular filtration.
Not metabolized; eliminated unchanged via glomerular filtration by the kidneys.
Primarily renal (glomerular filtration), with >95% of administered dose excreted unchanged in urine within 24 hours. Less than 1% is excreted via bile/fecal route.
Renal: 95% unchanged via glomerular filtration; Biliary: <5%; Fecal: <1%
Iopamidol (active ingredient) is minimally protein bound (<5%), primarily to albumin.
Negligible (<5%); no specific binding proteins
Approximately 0.20–0.30 L/kg, indicating distribution primarily within extracellular fluid space; low tissue binding.
0.3–0.4 L/kg (confined to extracellular space; does not cross intact blood-brain barrier)
Not applicable for oral route as it is used only intravascularly or intrathecally; bioavailability is 100% for IV injection and near 100% for intra-arterial and intrathecal administration.
Intravenous/Intra-arterial: 100%; Oral: 0% (not absorbed)
GFR <30 m L/min: Use with caution; consider lower dose and ensure adequate hydration. GFR <15 m L/min: Avoid use unless essential; post-procedure hemodialysis may be considered. No specific dose reduction formula; clinical judgment advised.
Contraindicated in patients with GFR <30 m L/min/1.73m². For GFR 30-59 m L/min, reduce dose by 50% and ensure adequate hydration.
No specific Child-Pugh based dose adjustments; use cautiously in severe hepatic impairment due to altered pharmacokinetics.
No specific Child-Pugh based adjustments; use caution in severe hepatic impairment due to risk of hepatorenal syndrome.
Weight-based: 1-2 m L/kg (300 mg iodine/m L) intravenously; maximum total dose 300 mg iodine/kg. Adjust for body habitus and procedure.
Intravenous: 0.5-1 m L/kg (maximum 2 m L/kg) for urography; not recommended for neonates due to risk of acute renal failure.
Elderly patients may have reduced renal function; assess GFR and adjust dose accordingly. Ensure adequate hydration before and after procedure. Monitor for nephrotoxicity and hypersensitivity.
Reduce dose by 25-50% in patients >70 years; maintain hydration and monitor renal function.
No FDA boxed warning.
Risk of severe, life-threatening adverse reactions including anaphylaxis, cardiovascular collapse, and seizures. Use only when diagnostic information is essential. Resuscitative equipment and trained personnel must be immediately available.
Risk of serious hypersensitivity reactions (including anaphylaxis),Acute kidney injury in patients with pre-existing renal impairment or other risk factors,Thyroid dysfunction (especially in neonates) due to iodine load,Pregnancy and lactation considerations
Risk of acute renal failure, particularly in patients with pre-existing renal impairment, diabetes, or dehydration. Caution in patients with cardiovascular disease, asthma, or known hypersensitivity. Avoid extravasation. Thyroid function tests may be affected. Ensure adequate hydration before and after administration.
Known hypersensitivity to iopamidol or any components of the formulation,History of severe adverse reaction to iodinated contrast agents
Absolute: Known hypersensitivity to iodinated contrast media, overt thyrotoxicosis, anuria or severe oliguria due to renal disease. Relative: Myeloma, pheochromocytoma, sickle cell disease, pregnancy, and concomitant use of nephrotoxic drugs.
No specific food interactions. However, patients are typically advised to avoid solid food for a few hours before the procedure (e.g., 4-6 hours NPO prior to injection) to reduce the risk of aspiration if emesis occurs. Also, ensure adequate hydration: recommend clear liquids (water, juice) unless contraindicated (e.g., pre-procedure fasting for other reasons).
No specific food interactions. Maintain adequate hydration; alcohol should be avoided as it may increase dehydration risk.
Iodinated contrast agents like Isovue-300 (iopamidol) cross the placenta. First trimester: Avoid unless essential; theoretical risk of fetal hypothyroidism from free iodide. Second/third trimester: Risk of transient neonatal hypothyroidism if high doses used; fetal goiter reported. No teratogenic effects at clinical doses in animal studies.
HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is an iodinated contrast agent. In animal studies, no teratogenic effects were observed. In humans, there is no evidence of fetal harm from diagnostic doses, though theoretical risks from free iodide exist, especially in the third trimester. The American College of Radiology recommends use only if clearly needed, with minimal dose.
Iopamidol is excreted into breast milk in small amounts (<1% of maternal dose). M/P ratio not established. Discontinue breastfeeding for 12-24 hours after administration, or pump and discard. Use only if clearly needed.
Iodinated contrast agents are excreted into breast milk in very small amounts (<0.01% of maternal dose). The M/P ratio is not established. Breastfeeding can continue without interruption, but some sources suggest discarding milk for 12-24 hours if desired.
No specific dose adjustments for pregnancy; use lowest effective dose. Increased plasma volume may slightly dilute contrast, but no dose change recommended. Avoid in patients with impaired renal function or hyperthyroidism.
No dose adjustment is recommended for pregnancy. However, use the lowest necessary dose to achieve diagnostic image. Renal function may be altered in pregnancy; ensure adequate hydration to prevent contrast-induced nephropathy.
ISOVUE-300 (iopamidol) is a nonionic, low-osmolality iodinated contrast medium used for intravascular and intrathecal administration. Key pearls: 1) Pre-hydrate patients with normal saline to reduce risk of contrast-induced nephropathy, especially in those with e GFR <30 m L/min/1.73m². 2) Screen for prior allergic-like reactions; consider premedication with corticosteroids (e.g., prednisone 50 mg PO q12h for 3 doses prior) and antihistamines (diphenhydramine 50 mg IV/PO 1 hour before) for history of moderate or severe reactions. 3) Avoid intrathecal use if there is suspicion of elevated intracranial pressure or CSF obstruction. 4) Metformin should be held for 48 hours post-procedure and only resumed after renal function recheck. 5) Have emergency equipment (oxygen, epinephrine, IV access) readily available for treatment of anaphylactoid reactions.
HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is a low-osmolar, ionic, dimeric contrast medium used for intravascular administration. It has lower osmolality than conventional ionic monomers, reducing the risk of contrast-induced nephropathy and hemodynamic disturbances. Ensure adequate hydration before and after administration. Caution in patients with renal impairment, diabetes, multiple myeloma, or prior contrast reactions. Do not mix with other drugs. Monitor for delayed hypersensitivity reactions.
This contrast agent may cause a warm sensation or metallic taste during injection; these sensations are temporary.,Notify the technologist immediately if you experience itching, hives, difficulty breathing, or swelling of the face or throat.,You should drink plenty of fluids (water) before and after the procedure to help clear the contrast from your kidneys unless otherwise instructed.,If you take metformin for diabetes, you may need to stop it for 48 hours after the procedure; your doctor will advise when to restart.,Inform your healthcare provider about any allergies (especially to iodine or contrast media), kidney problems, asthma, or if you are pregnant or breastfeeding.
Inform your doctor if you have kidney disease, diabetes, or any allergies, especially to contrast agents.,Drink plenty of fluids before and after the procedure to stay hydrated.,You may experience a warm sensation or metallic taste during injection; this is normal.,Report any symptoms like hives, itching, difficulty breathing, or swelling after the scan.,If you take metformin, you may need to stop it temporarily as directed by your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOVUE-300 vs HEXABRIX, answered by our medical review team.
ISOVUE-300 is a Contrast Media that works by Iodinated radiocontrast agent that attenuates X-rays, providing enhanced visualization of vascular structures and body cavities during imaging procedures.. HEXABRIX is a Contrast Media that works by Hexabrix is an ionic, high-osmolar iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during radiographic procedures. Its mechanism is physical rather than pharmacological, based on iodine's atomic number and density.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOVUE-300 and HEXABRIX depend on the specific clinical indication. These are both Contrast Media agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOVUE-300 is: Intravenous: 50-150 m L (up to 300 mg iodine/kg) as a bolus or infusion; intra-arterial: 5-40 m L depending on procedure; intrathecal: 8-15 m L. Maximum total iodine dose: 300 mg iodine/kg.. The standard adult dose of HEXABRIX is: Intravenous: 0.3-0.6 m L/kg (maximum 100 m L) for urography; 40-80 m L for CT enhancement.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOVUE-300 and HEXABRIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOVUE-300 is classified as Category C. Iodinated contrast agents like Isovue-300 (iopamidol) cross the placenta. First trimester: Avoid unless essential; theoretical risk of fetal hypothyroidism from free iodide. Second. HEXABRIX is classified as Category C. HEXABRIX (ioxaglate meglumine and ioxaglate sodium) is an iodinated contrast agent. In animal studies, no teratogenic effects were observed. In humans, there is no evidence of feta. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.